Search
Highlights of Past EHA (HOPE) Asia 2023
EHA joined forces with the Indian Society of Hematology & Blood Transfusion (ISHBT) to organize the 5th edition of the Highlights of Past EHA (HOPE) Asia 2023 meeting.
Read moreHighlights of Past EHA (HOPE) Asia 2020
EHA is returning to Sri Lanka for the 2nd edition of the Highlights of Past EHA (HOPE) Asia, organized with our hosting partner: the Sri Lanka College of Haematologists (SLCH).
Read moreHighlights of Past EHA (HOPE) Asia 2021
For the third edition of the Highlights of Past EHA (HOPE) Asia, EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.
Read moreHighlights of Past EHA (HOPE) MENA 2021
For the upcoming edition of the Highlights of Past EHA (HOPE) Middle East and North Africa (MENA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.
Read moreEuropean Affairs Committee
Committee members
Elizabeth Macintyre, France (Chair)
Antonio Almeida, Portugal
Natacha Bolaños, Spain (Patient advocate)
Lorenzo Brunetti, Italy
Raffaella Colombatti, Italy
Julio Delgado, Spain
Isabelle Durand-Zaleski, France (Advisory member)
Tarec El-Galaly, Denmark
Martin Kaiser, Germany
Frank Leebeek, The Netherlands (Advisory member)
Kate Morgan, United Kingdom (Patient advocate)
Marek Mraz, Czech Republic
Kostas Stamatopoulos, Greece
AimThe…
Hospital pharmacists and regulators lead the way on shortages
EHA welcomes initiatives but calls for more focus on causes
Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.
Scientific networks
Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.
Read moreAdvances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia
In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.
Read moreEHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials
EHA has responded to the EMA’s call for comments on the reflection paper on February 15.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- »